Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

Stephen George, Ph.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: May 9, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application Junovan (mifamurtide), formerly known as (L-MTP-PE, liposomal muramyl tripeptide phosphatidyl ethanolamine), sponsored by IDM Pharma, Inc., for treatment of high-grade resectable non-metastatic osteosarcoma in combination with adjuvant chemotherapy for osteosarcoma. Genzyme Corporation, NOF Corporation, Ben Venue Laboratories, owned by Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, and Solvias AG are the contract manufacturers of the liposomal formulation of muramyl tripeptide phosphatidylethanolamine. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Data Monitoring Committee	Competitor	Less than \$10,001 per year.
Unrelated Steering Committee	Contract Manufacturer for the Sponsor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

Signature of SGE

Date